Casper, the first well-known startup to lay out plans to go public this year, put its expected share price at the low end of the company’s already-reduced range
Casper Sleep Inc. priced its IPO at the low end of its already slashed range, the latest sign that the path to public ownership remains treacherous for unprofitable startups.
Casper pegged its share price at $12 on Wednesday just over a week after the mattress seller had said it expected its stock to price between $17 and $19 a share. On Wednesday morning, the company lowered its expected price range to $12 to $13, signaling it had struggled to find enough demand at higher levels.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Casper cuts expected IPO price range to $12-$13 a share from $17-$19 a shareCasper Sleep disclosed in a government filing that it would cut its initial public offering price to a range between $12 and $13 per share.
Read more »
Casper Sleep lowers IPO price range, implying valuation of just over $500 millionCasper Sleep Inc. lowered the price range for its planned initial public offering on Wednesday to $12 to $13 a share from a previous $17 to $19, a move that...
Read more »
Casper Sleep slashes the price range for its planned IPO - Business InsiderIt's a fraction of the $1.1 billion valuation private markets gave Casper in its last funding round.
Read more »
Casper Slashes IPO Price Range, Lowering Its Valuation To Around $500 MillionSeveral early investors stand to lose money after the mattress company lowered expectations around its IPO.
Read more »
Casper Slashes IPO Price Range, Lowering Its Valuation To Around $500 MillionOnline mattress startup Casper slashes IPO price range, lowering its valuation to around $500 million by skleb1234
Read more »
Breakingviews TV: Casper IPO | Reuters VideoThe online mattress firm slashed its valuation by another 30% ahead of its stock-market debut. M&A options may get kicked out of bed, too, given regulatory scrutiny of the deal for shaving startup Harry’s. Jennifer Saba explains why this doesn’t bode well for investors.
Read more »